Market Watch

Alembic Pharmaceuticals Ltd.

AS ON 23 15 PM | 23 201
AS ON 23 15 PM | 23 201
NSE
BSE
536.80-1.60-0.30%
Today's Trend
Low
435.15
High
639.90
Volume
16014.00
Open
538.00
Prev Close
538.40
535.20-2.90-0.54%
Today's Trend
Low
435.10
High
636.50
Volume
752.00
Open
523.00
Prev Close
538.10
x
Add to Portfolio
Add to Watchlist

Technical Chart

  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
Bid
Offer

Mkt Cap (₹ Cr.)

10127.07
10127.07

Face Value (₹)

2.00
2.00
P/E (x)
16.51
16.46
EPS-TTM(₹)
32.52
32.52
P/B (x)
3.72
3.71
BV/Sh(x)
144.18
144.18
Div. Yield(%)
1.02
1.03
52Wk L/H
435.15
639.90
435.10
636.50


News & Recos

  • Announcement under Regulation 30 (LODR)-Press Release / Media Release
    With reference to the captioned subject, this is to inform the exchange that the Companys joint venture, Aleor Dermaceuticals Limited, has received US Food and Drug Administration (USFDA) Approval for Clobetasol Propionate Topical Solution USP, 0.05%. Please find enclosed herewith our press release. We request you to kindly take the same on record.
  • Announcement under Regulation 30 (LODR)-Newspaper Publication
    Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a copy of Notice of Board Meeting published in English and vernacular language (Gujarati) newspaper on 15th October, 2019 in Economic Times English and Gujarati Edition. We request you to kindly take the same on record.
  • Announcement under Regulation 30 (LODR)-Newspaper Publication
    Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a copy of advertisement related to notice of loss of share certificates published by the Company on behalf of the shareholder(s) and / or legal heir(s) of the registered shareholder(s) in English language newspaper - Business Standard on 16th October, 2019. We request you to kindly take the same on record.
  • Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
    The exchange is hereby informed that the Company will hold Post Results Conference Call on 24th October, 2019 as per the enclosed details. We request you to kindly take the same on record.
  • Board Meeting Intimation for Board Meeting To Consider Unaudited Financial Results For The Quarter And Half Year Ended 30Th September, 2019
    ALEMBIC PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/10/2019 ,inter alia, to consider and approve With reference to the captioned matter, the exchange is hereby informed that a Meeting of Board of Directors of the Company will be held on Thursday, 24th October, 2019, inter-alia to consider and approve Unaudited Financial Results of the Company for the quarter and half year ended 30th September, 2019. Pursuant to the Companys Code of Conduct for Regulating, Monitoring and Reporting of Trading by Designated Persons and their Immediate Relatives, the trading window for dealing in securities of the Company which was closed from 1st October, 2019, will re-open 48 hours after the declaration of the financial results on 24th October, 2019. We request you to kindly take the same on record.
  • Compliance Certificate Pursuant To Regulation 7(3) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
    With reference to the captioned subject, we hereby confirm that all activities in relation to both physical and electronic share transfer facility are maintained by the Companys Registrar and Share Transfer Agent viz. Link Intime India Private Limited, which is a SEBI approved Category-I Registrar & Transfer Agent, registered with the Securities and Exchange Board of India (SEBI Registration Number: INR000004058). We request you to kindly take the same on record.
  • Shareholding for the Period Ended September 30, 2019
    Alembic Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2019. For more details, kindly Click here
  • Certificate Under Regulation 40(9) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Half Year Ended 30Th September, 2019
    With reference to the captioned subject, we enclose herewith Certificate under Regulation 40(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the half year ended 30th September, 2019, issued by M/s. Samdani Shah & Kabra, Practising Company Secretaries, Vadodara. We request you to kindly take the same on record.
  • Statement Of Investor Complaints For The Quarter Ended September 2019
    No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter
    0440
    Name of the Signatory :- Charandeep Singh Saluja
    Designation :- Company Secretary and Compliance Officer
  • Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
    With reference to the captioned matter, please find enclosed herewith a Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th September, 2019, received from M/s. Link Intime India Private Limited, Registrar and Share Transfer Agent of our Company. We request you to kindly take the same on record.
MORE FROM NEWS & RECOS
Alembic Pharmaceuticals Ltd. share price
down -0.30%
down -0.54%
from its previous close of Rs
538.40
538.10
. Alembic Pharmaceuticals Ltd. stock last traded price is
536.80
535.20
Alembic Pharmaceuticals Ltd. Share Price
Value
Today/Current/Last
536.80
535.20
Previous Day
538.40
538.10

Earnings
(Figures in Rs. Cr.)

Sales

Other Operating
Income

Operating Profit

Other Income

EBITDA

Interest

Depreciation

Tax

Net Profit

EPS (₹)

Jun 2019
% Chg (Quarterly)
% Chg (Yearly)
Peer Range
Trend
948.91
2.37
10.01
0.00
8374.36
0.00
0.00
0.00
0.00
115.06
224.92
26.33
48.97
-95.02
2805.84
3.29
-2.37
3190.00
0.00
430.10
228.21
25.80
51.05
-95.02
2805.84
4.98
-1.97
217.20
0.00
122.00
35.40
18.20
28.26
0.00
457.13
35.96
141.34
14.01
-40.98
227.98
119.49
-3.40
32.08
-94.19
1387.48
6.56
-0.30
36.67
-9.29
40.74

Stock Performance

Period:
LTP
%Change
Trend
536.80
-0.30
129.30
-2.49
299.20
0.03
421.25
-0.98
575.20
-0.35
565.60
4.55
348.00
1.84
1006.00
0.15
330.95
1.29
840.95
2.31
945.45
1.97

Financial Performance

LTP
(₹)
Market Cap
(Cr.)
Price to
Book
Price to
Earnings
PAT
Margins
RoE%
RoA%
Debt to
Equity
Avg. Cost
of Funds%
Current
Ratio
536.80
10119.53426352
3.72310063
14.49520041
14.8500
14.8356
12.3572
0.18360000
3.3400
1.78490000
299.20
8442.47122752
1.50629174
13.93843989
9.3700
9.6804
6.9763
0.63750000
1.2100
2.15110000
575.20
10462.16037200
3.01105169
71.39457057
30.7600
14.2049
15.5859
0E-8
3.1700
5.33040000
1006.00
8778.48376200
3.91145340
23.77446583
18.8200
14.2062
14.7786
0.00020000
3.5400
2.82660000
565.60
9008.94122184
1.87334455
22.32477876
6.3000
10.9957
5.0598
0.88220000
1.1600
2.50590000
945.45
11945.96014541
3.80695637
177.31869000
11.7800
10.8625
10.0408
0.04510000
0.4800
2.28160000
330.95
13238.00000000
3.36262955
62.95116268
18.1600
15.6956
11.0996
0.18370000
0.0000
1.13040000
421.25
5793.02085888
4.95626136
23.49099721
29.6000
14.8666
24.2773
0.00020000
0.0000
1.13000000
840.95
14652.24809103
2.68498868
62.19384563
10.4500
12.2973
8.4420
0.30980000
2.1500
2.77900000
129.30
3388.27425258
11.43782177
-48.53565754
-79.5200
37.4290
-77.3983
0.00360000
0.0000
1.05010000
348.00
3720.62456520
2.37678618
22.14987090
4.0900
6.2903
2.8176
0.16600000
1.2300
1.91480000

Financial Comparison with peers

Management Efficiency

Return On Equity (%)

Return On Assets (%)

Return On Capital Employed (%)

Fixed Assets Turnover (x)

Profitability & Growth

Gross Profit Margin (%)

Operating Profit Margin (%)

Net Profit Margin (%)

Financial Strength
Liquidity

Quick Ratio (x)

Current Ratio (x)

Cash Ratio (x)

Solvency

Debt Equity Ratio (x)

Coverage Ratios

Cash Flows to Long Term Debt (x)

Peer
Average
Peer Range
Trend
21.49
8.87
-99.01
47.57
12.35
5.79
-27.48
26.25
14.83
6.57
-130.86
23.01
1.20
0.97
0.00
2.79
19.27
-8.77
-980.00
34.42
22.20
0.38
-896.19
37.94
14.85
2.06
-461.80
94.28
0.93
1.65
0.08
9.50
1.78
2.40
0.21
9.50
0.18
0.22
-0.52
1.40
0.18
0.27
0.00
1.77
1.31
3.76
0.00
45.52

Share Holding

  • Categories
    No. Of Shares
    %
  • Promoters
    136,552,693
    72.44
  • NoOfShares
    188,515,914
    100.00
  • GeneralPublic
    18,311,128
    9.71
  • ForeignInstitutions
    17,996,017
    9.55
  • NBanksMutualFunds
    9,615,185
    5.10
  • Others
    2,547,747
    1.35
  • FinancialInstitutions
    2,486,164
    1.32
  • ForeignPromoter
    1,006,980
    0.53

Mutual Fund Ownership

Category
Rating
No. of shares
%Change in Shares
(MOM basis)
% of AUM
Amount Invested
(in ₹ Cr)
Equity: ELSS
1689516
0.00%
1.4%
86.06
Equity: Multi Cap
1034676
0.00%
1.24%
52.71
Equity: Mid Cap
1000000
0.00%
0.78%
50.94
Equity: Large & MidCap
979329
0.00%
1.38%
49.89

Liquid, Ultra Short Term funds and FMPs are not taken into account.

More Schemes

About

Alembic Pharmaceuticals Ltd., incorporated in the year 2010, is a Mid Cap company (having a market cap of Rs 10127.07 Crore) operating in Pharmaceuticals sector.

Alembic Pharmaceuticals Ltd. key Products/Revenue Segments include Pharmaceuticals which contributed Rs 3533.84 Crore to Sales Value (96.54 % of Total Sales), Export Incentives which contributed Rs 88.18 Crore to Sales Value (2.40 % of Total Sales), Royalty Income which contributed Rs 30.67 Crore to Sales Value (0.83 % of Total Sales) and Other Operating Revenue which contributed Rs 7.58 Crore to Sales Value (0.20 % of Total Sales)for the year ending 31-Mar-2019.

For the quarter ended 30-06-2019, the company has reported a Consolidated sales of Rs 948.91 Crore, up 2.37 % from last quarter Sales of Rs 926.95 Crore and up 10.01 % from last year same quarter Sales of Rs 862.53 Crore Company has reported net profit after tax of Rs 119.08 Crore in latest quarter.

The company’s top management includes Dr.Archana Hingorani, Mr.Chirayu Amin, Mr.K G Ramanathan, Mr.Paresh Saraiya, Mr.Pranav Amin, Mr.Pranav Parikh, Mr.R K Baheti, Mr.Shaunak Amin. Company has K S Aiyar & Co. as its auditoRs As on 30-09-2019, the company has a total of 188,515,914 shares outstanding.

Loading data...
Text Size:AAA

*

Markets Data
GetET MarketsAPP